MyFiziq teams up with NuraLogix to develop total health smart phone technology
MyFiziq Limited (ASX:MYQ) has signed a memorandum of understanding (MOU) with Canadian based NuraLogix Corporation.
MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimension using only a smartphone privately and accurately.
NuraLogix is a pioneer of Affective Artificial Intelligence (AI) which is the combination of affective computing and artificial intelligence. It has developed the world’s first cloud-based Affective AI Engine, DeepAffexTM, which utilises the company’s proprietary facial imaging technology, Transdermal Optical Imaging (TOITM).
This is used to predict a wide array of human physiological and psychological effects using nothing more than the video camera found on any smartphone.
Using this technology, the company developed the world's first smartphone app, AnuraTM, which can inform you about your general health and wellness in 30 seconds.
NuraLogix’ patented technology utilises a video camera like that found on a smartphone to take a 30-second selfie video of your face, determining a wide range of physiological and health-related parameters.
These include heart rate, heart rate variability, blood pressure, stress, cardiovascular disease risks and much more with TOI using the video camera to extract blood flow information from the face which is then processed by DeepAffexTM advanced machine learning algorithms that form part of the group’s cloud-based Affective AI Engine.
The MyFiziq image dimensioning capabilities will be combined with DeepAffex and Transdermal Optical Imaging to form a never before seen total health screen from a mobile phone.
The combined digital capability of the two companies, that is due to their patent coverage along with the unique offering, is a one of a kind non-invasive solution that can be used regardless of age.
Applications in gaining advanced warning of chronic health conditions
The resulting information captures and data are assisting individuals in understanding their personal exposure to chronic debilitating diseases that form up to 70% of deaths globally each year, including those that are primarily characterised by irregular blood pressure, heart and respiratory levels.
Consequently, users stand to benefit from seeing the early warning signs of cardiovascular disease, type II diabetes risk and stroke.
Commenting on the significance of these developments and the potential to develop proprietary technologies for a broad market, MyFiziq chief executive Vlado Bosanac said, “This is an extremely exciting partnership for the companies.
‘’Bringing our technologies together will not only create a one of a kind solution, furthermore it will be unrivalled.
‘’Our offerings in a standalone environment have a deep patent suite.
‘’When combining the company solutions, we not only form a unique offering, but one that enhances both companies’ ability to be the dominant player in digital health and convenience.
‘’The solutions form an easy to use, comprehensive review of an individual, accurately, privately, and conveniently from their mobile phone.’’
Opportunity to participate in COVID-19 symptoms analysis
Furthermore, users will have the option to engage in an in-app COVID-19 symptoms analysis, which has been developed and tested, by NuraLogix in collaboration with St. Michael’s Hospital, University of Toronto, and Zhongda Hospital in China to produce an AI based model which was trained and tested on the symptom’s profiles of COVID-19 patients.
The model predicts the likelihood of someone having COVID-19 versus seasonal flu or cold.
NuraLogix has been published previously for its work in determining health parameters via a mobile device in world leading publications such as The American Heart Association - Cardiovascular Imaging.
The doctors and clinicians that collaborated with NuraLogix in concluding the COVID-19 study have determined the outcome to be so significant that the results are being presented for publication.
The Anura COVID sample screen is shown below.
Global organisations have been exploring the potential combination of thermal imaging cameras with drone technology to scan crowds as a measure in the fight against current and future pandemics.
NuraLogix has been looking to be less invasive from a personal perspective, allowing individuals the choice to screen themselves at home or work when they feel they may have been exposed and are showing any of the known symptoms.
An integrated solution for global markets
Under the terms of the MOU, the parties have agreed to develop the application in a demonstrated mobile application (Demo App) combining their technologies to be used to evaluate the potential for a full commercial version of the application over the next 90 day period (Term).
At the end of the Term, should both parties consider the response of potential customers to the Demo App to be promising enough for further pursuit, they shall then negotiate a formal commercial agreement to specify terms including, but not limited to, pricing, revenue sharing, intellectual property, development work and marketing.
MyFiziq and NuraLogix intend to integrate the patented solutions to expand the capabilities of their capture suite for a potential global market.
Initially, they will only offer the Demo App to The Serfaty Clinic in Brazil and WeSure/WeFit in Mainland China. Upon a successful outcome, the company will then look to take the offering to a broader global audience.
MyFiziq has undertaken the entirety of the integration to expedite the process, envisaging completion of the build in readiness for handover in the next 60 days.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.